Phaseline

Companies › Vaxart

Vaxart: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VXA-CoV2-3.3
Oral SARS-CoV-2 vaccine (KP.2 strain)
–Phase 2SARS-CoV2May 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06672055VXA-CoV2-3.3Phase 2SARS-CoV2Infectious diseaseMay 2027

From the company's SEC filings

Cash and short-term investments of $66m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Green Cross Osivax Artcline Shanghai HEP Pharmaceutical BiomX

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.